Researchers at the Montreal Heart Institute announced today results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a reduction of 39% in combined clinical outcomes including heart attacks, strokes, unstable angina, coronary revascularizations and cardiovascular deaths.
These patients also benefit from a reduction in the amount of atherosclerosis (thickened walls) in their vessels. The detailed results are published in the prestigious Journal Circulation Cardiovascular Genetics. This discovery may also pave the way for a new era in cardiovascular medicine, with personalized or precision drugs.
The team led by Drs Jean-Claude Tardif and Marie-Pierre Dubé performed the analysis of 5749 patients who received dalcetrapib or placebo and provided DNA in a clinical study. A strong association was discovered between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16, particularly for a specific genetic variant (rs1967309). In patients with the genetic profile AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared to placebo. Supporting evidence was also obtained from a second study, which showed that patients with the favourable genetic profile also benefited from a reduction in the thickness of their carotid artery walls with dalcetrapib.
“These results will lead to a genetics-guided clinical study in patients with the appropriate genetic background to allow review by health regulatory agencies and to provide personalized therapy with dalcetrapib. It also offers great hope for precision treatments for patients with cardiovascular diseases and for curbing atherosclerosis, the first cause of mortality in the world” said lead investigator Jean-Claude Tardif MD, director of the Research Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.
The Latest on: Therapy for cardiovascular disease
via Google News
The Latest on: Therapy for cardiovascular disease
- Are obesity and diabetes offsetting progress made in heart disease?on January 25, 2022 at 9:05 am
Despite the advances in treatment and lifestyle changes, the prevalence rates of coronary heart disease have not been declining significantly in the U.S.
- 89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Healthon January 25, 2022 at 4:06 am
Inc (NASDAQ: ETNB) announced topline results from a cohort of 20 patients (Cohort 7) in the Phase 1b/2a proof-of-concept study evaluating pegozafermin (formerly BIO89-100) for nonalcoholic ...
- Understanding the prevention and treatment needs for cardiovascular diseaseon January 25, 2022 at 2:12 am
While there has been some progress in understanding the prevention and treatment needs for CVD, it often does not receive the attention it duly deserves. As an industry, we have a responsibility to ...
- 89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data seton January 24, 2022 at 12:05 pm
NASH treatments with new top-line data from a limited number of patients that show its candidate spurred improvements in disease severity based on several measures.
- My heart will go on: Patient-derived heart cells mimic disease in vitroon January 24, 2022 at 9:58 am
Researchers have found that induced pluripotent stem cell--derived cardiomyocytes from a patient with arrhythmogenic cardiomyopathy recapitulate the reduced contractility and impaired desmosome ...
- UofL researchers develop gene therapy to regenerate heart muscle cellson January 24, 2022 at 8:07 am
A University of Louisville research team has refined a process in which specific genes administered to heart muscle cells stimulate the cells to divide, with the goal of restoring heart function ...
- Patient-derived heart cells mimic disease in vitroon January 24, 2022 at 6:39 am
How can you mend a broken heart? According to researchers from Japan, in some cases gene replacement therapy just might do the trick.
- Oral Penicillin Advised for High-Risk Rheumatic Heart Diseaseon January 20, 2022 at 1:35 pm
Some patients with rheumatic heart disease who are thought to have an allergic response to injectable penicillin may actually be experiencing a cardiac reaction to the injection, a new AHA advisory ...
- Pediatric Patients With Cardiovascular Disease Receive Multiple Off-Label Drugson January 14, 2022 at 6:15 am
Researchers assessed the off-label use of cardiovascular medications in a home therapy setting for children with congenital or acquired heart disease.
- Novel treatment target for heart disease found in the blood vessel wallon January 13, 2022 at 11:37 pm
A molecule of RNA called CARMN has been found in abundance in the healthy smooth muscle cells that help give our blood vessels strength and flexibility, and distinctly decreased in vascular diseases ...
via Bing News